Amatuximab is a humanized monoclonal antibody directed to mesothelin that kills mesothelin-expressing tumor cells by antibody-dependent cell-mediated cytotoxicity. Amatuximab blocks the binding of mesothelin to CA 125 and thus could be used also as a strategy to prevent tumor metastasis.